Table 2

Treatment

MPM (n=11 539)MPeM (n=629)Total (N=12 168)
All, n (%)*
 Chemotherapy3273 (28.4)142 (22.6)3415 (28.1)
 Surgery343 (3.0)65 (10.3)408 (3.4)
 Radiotherapy1072 (9.3)4 (0.6)1076 (8.8)
 Immunotherapy52 (0.5)3 (0.5)55 (0.5)
 Targeted therapy72 (0.6)2 (0.3)74 (0.6)
 Best supportive care7132 (61.8)423 (67.2)7555 (62.1)
 Unknown144 (1.2)7 (1.1)151 (1.2)
Multimodal treatment, n (%)
 Chemotherapy and surgery92 (0.8)10 (1.6)102 (0.8)
 Chemotherapy and radiotherapy252 (2.2)1 (0.2)253 (2.1)
 Chemotherapy and targeted therapy44 (0.4)1 (0.1)45 (0.4)
 Chemotherapy and immunotherapy11 (0.1)11 (0.1)
 Surgery and radiotherapy47 (0.4)2 (0.3)49 (0.4)
 Surgery and chemotherapy and radiotherapy40 (0.3)40 (0.3)
 Other9 (0.1)3 (0.5)12 (0.1)
 Total495 (4.3)17 (2.7)512 (4.2)
Reason for no treatment (ie, BSC), n (%)†
 Comorbidity18 (2.1)3 (5.9)21 (2.3)
 Performance status214 (25.3)16 (31.4)230 (25.6)
 Age32 (3.8)1 (2)33 (3.7)
 Patient preference363 (42.9)14 (27.5)377 (42)
 Disease too extensive55 (6.5)8 (15.7)63 (7)
 Deceased before start of treatment30 (3.5)0 (0)30 (3.3)
 Other/unknown135 (15.9)9 (17.6)144 (16)
  • *Total percentage >100% due to 4.2% of patients receiving multimodal treatment.

  • †Registered for 898 patients (847 pleural, 51 peritoneal); percentages based on registered cases.

  • BSC, best supportive care; MPeM, malignant peritoneal mesothelioma; MPM, malignant pleural mesothelioma.